1. New ESMO Guidance on Tumor Sidedness in mCRC

3. Introduction

4. Pathological Distinctions Between CRC Tumors

5. mCRC Is a Molecularly Heterogeneous Disease

6. ESMO Position Paper on the Role Tumor Sidedness and Efficacy of Anti-EGFR Therapy

7. Clinical Trials Included in the Analysis

8. ESMO Position Paper: Caveats of the Study

9. Prognostic and Predictive Analyses of Tumor Sidedness

10. ESMO Position Paper: Summary of Findings

11. Forest Plots of Predictive Analyses for ORR, EGFRi + Chemo vs Chemo ± Bevacizumab

12. Forest Plots of Predictive Analyses for PFS, EGFRi + Chemo vs Chemo ± Bevacizumab

13. Forest Plots of Predictive Analyses for OS EGFRi + Chemo vs Chemo ± Bevacizumab

14. First-Line Treatment Choice for RAS and BRAF Wild-Type Left-Sided Tumors

15. Pan-Asian Adapted ESMO Consensus Guidelines

16. Optimal Treatment Choices for Cytoreduction by Location of Primary Tumor

17. Optimal Treatment Choices for Disease Control by Location of Primary Tumor

18. The European Perspective on the ESMO Position Paper on Tumor Sidedness

19. First-Line Treatment Choice for RAS and BRAF Wild-Type Right-Sided Tumors

20. Pan-Asian ESMO Consensus Guidelines Now Published

21. Discussion Summary: Key Points

22. Discussion Summary: Key Points (cont)

23. Abbreviations

24. Abbreviations (cont)